Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A, Zhivotovsky B, Jernberg-Wiklund H, Grandér D, Celsing F, Björkholm M, Vanderkerken K, Panaretakis T. Kharaziha P, et al. Among authors: celsing f. Cancer Res. 2012 Oct 15;72(20):5348-62. doi: 10.1158/0008-5472.CAN-12-0658. Epub 2012 Sep 4. Cancer Res. 2012. PMID: 22952216
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Lundin J, Osterborg A, Björkholm M, Björkstrand B, Celsing F, Hjalmar V, Linder O, Luthman M, Merup M, Tidefelt U, Mellstedt H; Myeloma Group of Central Sweden. Lundin J, et al. Among authors: celsing f. Hematol J. 2003;4(4):248-52. doi: 10.1038/sj.thj.6200301. Hematol J. 2003. PMID: 12872149 Clinical Trial.
Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
Osterborg A, Björkholm M, Björeman M, Brenning G, Carlson K, Celsing F, Gahrton G, Grimfors G, Gyllenhammar H, Hast R, et al. Osterborg A, et al. Among authors: celsing f. Blood. 1993 Mar 15;81(6):1428-34. Blood. 1993. PMID: 8453092 Free article. Clinical Trial.
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A. Lundin J, et al. Among authors: celsing f. Blood. 2002 Aug 1;100(3):768-73. doi: 10.1182/blood-2002-01-0159. Blood. 2002. PMID: 12130484 Free article. Clinical Trial.
48 results